The consensus among the panel is bearish on Conagra (CAG) due to structural issues such as brand obsolescence, declining sales, and high debt levels. A potential earnings beat may provide temporary relief but is unlikely to address the core problems.
Risk: Ongoing volume erosion and loss of market share to health-conscious alternatives.
Opportunity: Potential debt reduction through dividend savings and a strategic pivot under new CEO John Brase.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Key Points
- Analysts tracking the stock expect year-over-year declines in both revenue and profitability.
- So a convincing beat on either metric could easily give a meaningful lift to the shares.
- 10 stocks we like better than Conagra Brands ›
This coming Hump Day is going to be an important one for Conagra Brands (NYSE:CAG). …
Read more
Key Points
- Analysts tracking the stock expect year-over-year declines in both revenue and profitability.
- So a convincing beat on either metric could easily give a meaningful lift to the shares.
- 10 stocks we like better than Conagra Brands ›
This coming Hump Day is going to be an important one for Conagra Brands (NYSE:CAG). That morning, it's scheduled to publish its first quarterly earnings report for the current fiscal year (2027), and expectations are modest. Even so, the food company has missed analyst estimates more than once in the recent past, and if that happens again, its already-beaten-down stock could take another body blow.
Let's take a look at the expectations for first-quarter performance and gauge Conagra's prospects for that period and beyond.
Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
Image source: Getty Images.
Downward trajectories
The consensus analyst net sales estimate for Conagra's first quarter, i.e., the three-month stretch ending Aug. 31, is $2.59 billion. That's less than 2% below what the storied comestibles company earned in the same period of fiscal 2026.
Those pundits are modeling a far more dramatic drop in net income, as their collective estimate for the metric not under generally accepted accounting principles (non-GAAP, or adjusted) is $0.28 per share. Coincidentally, this is 28% below the year-ago result.
That downward dynamic isn't especially encouraging, however we should keep in mind that it's not unusual for Conagra to top expectations, if only modestly. In fact, it beat on adjusted earnings in three of the four reported fiscal 2026 quarters, with the only miss (for the third quarter figure) being a narrow one, at $0.39 per share versus the $0.40 per share analyst consensus.
Adjusting to the modern era
We can't ignore those low expectations, however, and we can't turn away from the continuing erosion of Conagra's key fundamentals. Zooming out some, annual net sales have fallen in every fiscal year since 2023. On top of that, the typically profitable company posted a fairly steep ($1.9 billion) GAAP net loss for 2026. Much of that was due to over $2.9 billion in non-cash impairment charges against legacy brands, plus goodwill.
However, while that means it's largely a paper loss, it still looms large in investors’ view. And even though the company posted an adjusted net profit, at $823 million it was well down from the previous year's more than $1.1 billion.
Earlier this year, management was compelled, for the sake of the finances, to cut the company's quarterly dividend. It chopped it in half, resulting in a quarterly payout of just under $0.18 per share. That was the first time since 2006 it reduced the dividend, by the way.
The downward trend in fundamentals is mainly due to the nature of Conagra's business. It's still holding on to its historical role as a purveyor of frozen and prepared foods. The Birds Eye line remains a supermarket freezer mainstay, as does Orville Redenbacher's popcorn in the snack aisle, and Slim Jim meat tubes in the checkout rack. We oldies who remember grocery shopping with Mom and Dad in decades past saw those same products in the same spots.
But the food business is always changing, because consumer tastes are constantly shifting. For years now, folks have become increasingly more health-conscious, and demand for healthy comestibles has increased precipitously. Witness the rise of organic products, for one; these goods basically only existed in health food stores in the old days. Remember those? Since then, they've gone wide and mainstream.
Meet the new boss
It can be hard for a veteran company to devise and execute a major strategic change, but at this point, that might just be what's needed for Conagra. In April, the company appointed a new CEO, John Brase. He's a long-serving food industry executive, so he's sure to have a good read on the current state of the industry. But it feels to me there's significant inertia at the company, and we haven't yet received any indication there will be a major change in its approach. If there are intimations of this in the upcoming earnings report, investors might be bullish enough to push the stock higher.
I'd say the same if Conagra manages a strong beat on either the top or bottom line. Or if it declares even a modest dividend raise. Would I bet on one of these two things to happen? At this point, no, but for the sake of both the company and its shareholders, it'd be nice if I'm wrong.
Should you buy stock in Conagra Brands right now?
Before you buy stock in Conagra Brands, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Conagra Brands wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $383,680! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,382,954!
Now, it’s worth noting Stock Advisor’s total average return is 937% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of September 28, 2026. *
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
“Conagra's recent impairment charges and dividend cut signal a structural decline in brand relevance that a single quarter's earnings beat cannot reverse.”
Conagra (CAG) is currently a classic 'value trap' scenario. While the article highlights the potential for a relief rally on a beat, it ignores the structural decay of the balance sheet. A 28% year-over-year decline in non-GAAP EPS expectations reflects a fundamental loss of pricing power in a category where private-label competition is cannibalizing market share. The 2026 impairment charges weren't just 'paper losses'; they were a recognition that their brand equity is fading. Until CEO John Brase provides a credible pivot toward higher-margin, health-conscious categories, any earnings-driven pop is merely an exit opportunity for institutional holders, not a fundamental inflection point.
If Conagra successfully slashes SG&A costs to offset volume declines, the resulting margin stabilization could trigger a massive short squeeze given the stock's depressed valuation.
“Beating depressed expectations on a 28% EPS decline won't reverse CAG's multi-year revenue erosion or address the fundamental shift in consumer preferences away from its core frozen-food portfolio.”
The article frames CAG as a 'beat could send it soaring' story, but that's backwards. A 28% EPS decline is baked in—consensus is $0.28 vs. $0.39 YoY. CAG beat three of four quarters in FY2026, yet the stock still got hammered due to structural headwinds: revenue down every year since 2023, $1.9B GAAP loss, dividend cut 50% for first time since 2006. A modest beat on a terrible baseline doesn't fix the core problem: CAG is a legacy frozen-food company losing relevance as consumers shift to fresh/organic/health-conscious alternatives. New CEO Brase is a positive signal, but the article admits 'significant inertia' and no strategic pivot yet announced. Earnings beat ≠ turnaround catalyst.
If Brase signals a credible M&A or portfolio transformation strategy on the call, or if adjusted margins stabilize despite revenue pressure, institutional investors could re-rate CAG as a restructuring story rather than a decline story—especially if the dividend cut was the capitulation moment.
“Conagra's legacy brand inertia and dividend cut signal deeper structural decline that low expectations alone cannot fix.”
The article frames CAG's Sep 30 earnings as a potential catalyst due to depressed consensus forecasts ($2.59B sales, $0.28 adj. EPS). Yet this overlooks the structural erosion: net sales have fallen every year since FY2023, FY2026 produced a $1.9B GAAP loss after $2.9B impairments, and the dividend was halved for the first time since 2006. Legacy brands like Birds Eye and Slim Jim face sustained pressure from health-conscious shifts, and the April CEO change has produced no visible strategy reset. A modest beat may provide temporary relief but does little to address portfolio obsolescence.
Beaten-down consumer staples names with low bars frequently post short-covering rallies on any in-line or slightly better print, especially if management offers even mildly improved FY2027 guidance.
“A single Q1 beat is unlikely to reverse Conagra's multi-year sales and margin decline without a credible, visible strategic pivot and sustained margin expansion.”
Event risk for Conagra: a beat could spark only a short-lived bounce, because the core story remains weak. The article highlights a modest Q1 guide and a big 2026 GAAP loss driven by over $2.9B in impairment charges; even with an earnings beat, price-to-sales and margins face secular pressure from health-conscious demand and rising input costs. The dividend cut signals ongoing balance-sheet discipline rather than reinvestment runway. Execution risk under new CEO John Brase adds uncertainty about a credible strategic pivot toward higher-growth categories. In short, a single quarterly beat is unlikely to resolve the multi-year trend of declining sales and profits, unless there is clear evidence of margin expansion and a real strategic shift.
The strongest counterargument: if Brase can deliver rapid cost reductions and a credible strategic pivot, margins might surprise to the upside. The market could underappreciate any timing mismatch between impairment optics and real operating recovery.
The Debate
Responding to Claude
“Conagra's high leverage and interest burden preclude a rapid strategic pivot through M&A, making a turnaround unlikely without significant asset divestitures.”
Claude and Grok focus heavily on brand obsolescence, but they ignore the balance sheet's leverage profile. With net debt-to-EBITDA likely north of 4x following the impairment-driven equity erosion, Conagra lacks the dry powder for the M&A-led transformation Claude suggests. Any 'restructuring story' is constrained by interest expense. The dividend cut wasn't just a capitulation; it was a desperate liquidity preservation move. Without aggressive divestitures of legacy assets, Brase is trapped in a low-growth, high-debt cycle.
Responding to Gemini
“Leverage is a real constraint, but the dividend cut's cash release and potential EBITDA stabilization could create more optionality than Gemini's 'trapped' framing suggests.”
Gemini's leverage point is critical but incomplete. Net debt-to-EBITDA north of 4x is real, but the article doesn't disclose current leverage ratios or covenant headroom. If CAG has covenant flexibility or if EBITDA stabilizes faster than sales decline (margin compression already priced in), debt ratios improve sharply. The dividend cut frees ~$300M annually—enough to fund modest divestitures without distressed asset sales. Brase's first move should clarify debt reduction vs. reinvestment sequencing on the call.
Responding to Gemini
“Dividend savings could accelerate deleveraging faster than Gemini allows, yet secular volume erosion still overrides any balance-sheet relief.”
Gemini flags the leverage trap correctly but underplays how the $300M annual dividend savings directly funds debt reduction without needing divestitures. If EBITDA holds even flat, net debt-to-EBITDA could drop below 4x by FY2027, easing covenant pressure. The real unaddressed risk is whether Brase can stabilize volumes at all; continued share loss would erase any balance-sheet gains regardless of interest expense.
Responding to Grok
“Dividends savings help, but debt reduction isn't guaranteed and hinges on EBITDA/margin recovery; leverage relief is conditional.”
Grok argues dividend savings fund debt reduction and even a lower leverage. My take: that assumes EBITDA stability in a shrinking-volume business, which is unlikely. Freed cash could be eaten by working capital needs, capex, or liquidity buffers, so net debt-to-EBITDA may not drop meaningfully without real margin improvements or asset sales. The core risk is ongoing volume erosion; relief is conditional, not a given.
Panel Verdict
BEARISH Consensus ReachedThe consensus among the panel is bearish on Conagra (CAG) due to structural issues such as brand obsolescence, declining sales, and high debt levels. A potential earnings beat may provide temporary relief but is unlikely to address the core problems.
Potential debt reduction through dividend savings and a strategic pivot under new CEO John Brase.
Ongoing volume erosion and loss of market share to health-conscious alternatives.
Related News
This is not financial advice. Always do your own research.